CATO SMS has unveiled its new brand, revealing an updated look and logo capturing the company’s offering following the merger of CATO Research, and Specialized Medical Services-oncology BV (SMS-oncology). As a fully integrated company, CATO SMS leverages 30 years of global experience to provide regulatory support and clinical trial solutions to small and emerging biopharmaceutical companies with a plan to make trials digital.
CATO and SMS-oncology joined in 2019 to expand their global footprint, deepen their oncology and regulatory expertise, and broaden their suite of services. As one company, CATO SMS offers a blend of capabilities specializing in supporting biopharmaceutical companies with advancing drug development. CATO SMS has conducted 500+ trials in more than 25 countries, focusing on some of the most complex development areas including oncology, rare and orphan indications, and cell and gene therapy. The company has contributed to the successful development of over 50 marketed products and includes a prolific regulatory group that completes approximately 750 submissions of various types annually.
“Our new brand reflects the value and insight CATO SMS brings to our clients as one organization,” said Mark A. Goldberg, M.D., executive chairman, CATO SMS. “We’ve formed a high-performance team across a variety of therapeutic areas, from our global regulatory experts to our center of excellence in oncology. We are excited to provide our clients with a broader set of solutions supported by the same high level of operational excellence and personalized customer service they have come to expect from us over the past three decades.”